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In 2011, five independent, international guideline committees reported their recommendations for the management of
symptomatic and asymptomatic carotid artery stenosis. These included the American College of Cardiology/American
Heart Association, the Society for Vascular Surgery, the European Society of Cardiology, the Australasian, and the UK
National Institute of Health and Clinical Excellence. As the recommendations of these five guideline committees were
based on the same published literature, it would be expected that they are similar, at least to a large extent. Surprisingly,
there were considerable differences between the five guidelines regarding the management of both symptomatic and
asymptomatic carotid patients. The differences in the recommendations between the five Guideline Committees are
analyzed and discussed. (J Vasc Surg 2012;55:1504-8.)
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eWith the introduction and widespread use of carotid
artery stenting (CAS), there is an ongoing debate regarding
the treatment of choice for symptomatic and asymptomatic
carotid artery stenosis. Possibly because of this controversy,
three different guideline committees reported their recom-
mendations for the management of symptomatic and
asymptomatic carotid stenosis in 2011, namely, the Amer-
ican College of Cardiology/American Heart Association
(ACC/AHA) Guidelines,1 the Updated Society for Vascu-
lar Surgery (SVS) Guidelines,2 and the European Society of
Cardiology (ESC) Guidelines.3 Two other guidelines com-
mittees also reported their recommendations in 2011 for
the indications for CAS4 and the role of CAS in the man-
agement of asymptomatic carotid stenosis.5
It would seem reasonable that these guidelines should
be similar because they were all based on the same pub-
lished literature. However, they differ substantially in sev-
eral regards. This article discusses the differences between
the recommendations of the five guideline committees1-5
and will also attempt to explain these differences and, where
possible, reconcile them.
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1504ATIENTS WITH SYMPTOMATIC CAROTID
RTERY STENOSIS
The UK National Institute for Health and Clinical
xcellence (NICE) guidelines included recommendations
nly for asymptomatic patients.5 Therefore, the recom-
endations of the remaining four guideline committees for
ymptomatic carotid artery stenosis appear in Table I.1-4
The ACC/AHA Guidelines recommend CAS as an
alternative” to carotid endarterectomy (CEA) for the
anagement of symptomatic carotid artery stenosis.1 This
mplies that CAS is an “equivalent” therapeutic option to
EA for symptomatic patients and has been interpreted in
his way by CAS enthusiasts.6-8 In symptomatic patients,
owever, CEA is associated with lower stroke and death
ates compared with CAS in all randomized trials to date.6,7
herefore, CAS should not be viewed at present as an
quivalent therapeutic option to CEA inmost symptomatic
atients.6,7 Admittedly, with better patient selection and
mproved CAS technology (eg, use of flow-reversal or
essation techniques,9,10 and better stents), CASmay prove
o be equal or superior to CEA in certain patient sub-
roups.6,7 However, currently this is not the case based on
he results of published randomized trials.
The updated SVS2 and the Australasian3 guidelines
ake this point and specifically recommend CAS only for
ymptomatic patients with tracheal stoma, scarred necks,
xternal beam radiotherapy, previous cranial nerve injury,
nd other specific conditions, as well as for patients with
omorbidities considered to be high-risk candidates for
EA.2,3 The 2011 SVS Guidelines2 for the management of
arotid stenosis are an update of the 2008 SVSGuidelines11
nd were produced in response to new trial data that have
merged since then. The recommendations of the ESC
uidelines4 approximate the updated SVS2 and the Aus-
Society of Cardiology; SVS, Society for Vascular Surgery.
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Guidelines Recommendation
ACC/AHA1 ● Prophylactic CAS might be considered in highly selected patients with asymptomatic carotid stenosis (minimum
60% by angiography, 70% by validated Doppler ultrasound), but its effectiveness compared with medical therapy
alone in this situation is not well established [class IIb; level of evidence, B].
Revised SVS2 ● Neurologically asymptomatic patients with 60% diameter stenosis should be considered for CEA for reduction of
long-term risk of stroke, provided the patient has a 3- to 5-year life expectancy and perioperative stroke/death rates
can be 3% [grade I; level of evidence, A].
● There are insufficient data to recommend CAS as primary therapy for neurologically asymptomatic patients with
70% to 99% diameter stenosis. In properly selected asymptomatic patients, CAS is equivalent to CEA in the hands of
experienced interventionalists with a combined stroke and death rate 3% [grade II; level of evidence, B].
ESC3 ● In asymptomatic patients with carotid artery stenosis 60%, CEA should be considered as long as the perioperative
stroke and death rate for procedures performed by the surgical team is 3% and the patient’s life expectancy exceeds
5 years [class IIa; level of evidence, A].
● In asymptomatic patients with an indication for carotid revascularization, CAS may be considered as an alternative
to CEA in high-volume centers with documented death or stroke rate 3% [class IIb; level of evidence, B].
Australasian4 ● There is currently no evidence to support CAS as a treatment for asymptomatic carotid stenosis.
NICE5 ● Current evidence on the safety of CAS placement for asymptomatic extracranial carotid stenosis shows well-
documented risks, in particular, the risk of stroke. The evidence on efficacy is inadequate in quantity. Therefore, this
procedure should only be used with special arrangements for clinical governance, consent, and audit or research.Table I. Recommendations of the 2011 carotid guidelines for patients with symptomatic carotid artery stenosis
Guidelines Recommendation
ACC/AHA1 ● CAS is indicated as an alternative to CEA for symptomatic patients at average or low risk of complica-
tions associated with endovascular intervention when the diameter of the lumen of the internal carotid
artery is reduced by more than 70% as documented by noninvasive imaging or more than 50% as docu-
mented by catheter angiography and the anticipated rate of periprocedural stroke or mortality is less than
6% [class I; level of evidence, B].
● Among patients with symptomatic severe stenosis (70%) in whom the stenosis is difficult to access sur-
gically, medical conditions are present that greatly increase the risk for surgery, or when other specific
circumstances exist, such as radiation-induced stenosis or restenosis after CEA, CAS may be considered
[class IIb; level of evidence, B].
● CAS in the above setting is reasonable when performed by operators with established periprocedural
morbidity and mortality rates of 4%-6%, similar to those observed in trials of CEA and CAS [class IIa;
level of evidence, B].
Revised SVS2 ● In most patients with carotid stenosis who are candidates for intervention, CEA is preferred to CAS for
reduction of all-cause and periprocedural death [grade I; level of evidence, B].
● CAS is preferred over CEA in symptomatic patients with 50% stenosis and tracheal stoma, situations
where local tissues are scarred and fibrotic from prior ipsilateral surgery or external beam radiotherapy,
prior cranial nerve injury, and lesions that extend proximal to the clavicle or distal to the C2 vertebral
body [grade II; level of evidence: B].
● CAS is preferred over CEA in symptomatic patients with 50% stenosis and severe uncorrectable coro-
nary artery disease, congestive heart failure, or chronic obstructive pulmonary disease [grade II; level of
evidence, C].
ESC3 ● In patients with symptomatic 70% to 99% stenosis of the internal carotid artery, CEA is recommended
for the prevention of recurrent stroke [class I; level of evidence, A].
● In symptomatic patients at high surgical risk requiring revascularization, CAS should be considered as an
alternative to CEA [class IIa; level of evidence, B].
● In symptomatic patients requiring carotid revascularization, CAS may be considered as an alternative to
CEA in high-volume centers with documented death or stroke rate 6% [class IIb; level of evidence, B].
Australasian4 ● CAS may be considered as a treatment option for patients with symptomatic severe carotid stenosis who
are at high risk of stroke, but are surgically unsuitable for CEA, namely postradiation therapy, block dis-
section of the neck, in situ tracheostomy, recurrent stenosis following previous CEA, severe cervical spine
arthritis, surgically inaccessible carotid stenosis (eg, obesity, high carotid bifurcation), contralateral recur-
rent laryngeal nerve injury, and contralateral internal carotid occlusion.
● The overall results of randomized controlled trials indicate that CAS is not as safe as CEA for treatment
of symptomatic carotid stenosis for prevention of ipsilateral stroke.
ACC/AHA, American College of Cardiology/American Heart Association; CAS, carotid artery stenting; CEA, carotid endarterectomy; ESC, EuropeanACC/AHA, American College of Cardiology/American Heart Association; CAS, carotid artery stenting; CEA, carotid endarterectomy; ESC, European
Society of Cardiology; NICE, UK National Institute for Health and Clinical Excellence; SVS, Society for Vascular Surgery.
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Guidelines.1 They provide a weak recommendation for
CAS as an alternative to CEA only in symptomatic patients
at high surgical risk or in high-volume centers with docu-
mented stroke and mortality rates 6%.4
PATIENTS WITH ASYMPTOMATIC CAROTID
ARTERY STENOSIS
The recommendations of the five guidelines for asymp-
tomatic carotid artery stenosis appear in Table II.1-5 Ac-
cording to the ACC/AHA Guidelines,1 CAS might be
considered as an option for asymptomatic carotid stenosis
(class IIb; level of evidence, B). In contrast, the SVS2 and
the Australasian3 guidelines indicate that there is currently
insufficient evidence to recommend CAS for asymptomatic
stenosis. The NICE Guidelines make clear that clinicians
wishing to undertake CAS for asymptomatic carotid steno-
sis should ensure that patients “understand the uncertainty
about the procedure’s efficacy, the risk of stroke and other
complications, and the reasons for advising CAS rather than
CEA or BMT alone in their particular case.”5 The ESC
Guidelines gave a class IIa recommendation for CEA and a
class IIb recommendation for CAS in asymptomatic pa-
tients.3 In addition, the ESC emphasizes that for CAS to be
performed in asymptomatic patients, it should be done in
high-volume centers with documented stroke and death
rates 3%.3 The NICE Guidelines5 are in agreement with
the ESC Guidelines.3
Large multicenter studies have demonstrated that CAS
and CEA are associated with similar outcomes in asymp-
tomatic patients.12,13 However, CAS is more expensive
than CEA.14,15 Furthermore, several recent analyses indi-
cate that best medical treatment (BMT) alone, without the
need for CAS or CEA, is sufficient for the management of
most asymptomatic carotid patients.16-18
The treatment of choice for asymptomatic carotid ste-
nosis therefore still remains uncertain. The results of the
Stent-Protected Angioplasty in Asymptomatic Carotid Ar-
tery Stenosis II (SPACE-II)19 study, a three-arm random-
ized trial comparing CEA vs CAS vs BMT, and perhaps
other similar studies, will help to better define the role of
BMT in patients with asymptomatic carotid stenosis. How-
ever, the results of these trials will not be known for many
years, and controversy in this field will continue.
DISCUSSION
A brief discussion of the recommendations of the five
guidelines is presented. Regarding symptomatic patients,
the updated SVS2 and the Australasian4 guidelines clearly
recommend CEA over CAS for most symptomatic patients
requiring intervention. Both guidelines list specific indica-
tions for CAS that apply only to a minority of symptomatic
patients. The ESCGuidelines3 also recommend CEA as the
gold standard for symptomatic patients and give a low-
strength recommendation for CAS in patients at high sur-
gical risk and in centers with documented stroke/death
rates6%. In contrast, the ACC/AHAGuidelines1 recom- gend CAS as an “alternative” to CEA for the management
f symptomatic carotid artery stenosis.
A possible explanation of the recommendations of the
CC/AHA Guidelines1 may be that the ACC/AHA was
isled by the results of the Carotid Revascularization End-
rterectomy vs Stenting Trial (CREST).12 CREST com-
ared CEA with CAS in both symptomatic and asymptom-
tic patients and concluded that “for 2,502 patients over a
edian follow-up period of 2.5 years, there was no signif-
cant difference in the estimated 4-year rates of the primary
nd point between the stenting group and the endarterec-
omy group (7.2% and 6.8%, respectively; hazard ratio
HR] with stenting, 1.11; 95% confidence interval [CI],
.81-1.51; P  .51).”12
The primary end point in CREST, however, included
he incidence rates of stroke, myocardial infarction, or
eath from any cause.12 When the percentages were ana-
yzed separately for each end point, CAS was associated
ith a nonsignificant (due to small numbers; P .18) more
han twofold higher risk for periprocedural death (9 CAS vs
CEA deaths; HR, 2.25; 95% CI, 0.69-7.30), a significant
P .01) an almost twofold increased risk for any peripro-
edural stroke (52 CAS vs 29 CEA strokes; HR 1.79; 95%
I, 1.14-2.82), and a highly significant more than twofold
ncreased risk for minor ipsilateral stroke (37 CAS vs 17
EA episodes; HR, 2.16; 95% CI, 1.22-3.83; P  .009)
ompared with CEA. However, patients undergoing CAS
uffered fewer myocardial infarctions compared with those
ndergoing CEA (14 vs 28, respectively; HR, 0.50; 95%
I, 0.26-0.94; P  .03).12 This difference balanced the
ifference in strokes and produced the apparent “equiva-
ence in the overall primary end point.” An analysis and
nterpretation of the CREST results is provided in greater
etail elsewhere.20
The revised SVS,2 Australasian,4 and NICE5 guidelines
onclude that there is currently insufficient evidence to
ecommend CAS for asymptomatic patients. In contrast,
he ESC3 and the ACC/AHA1 guidelines both provide
ecommendations that may bemisinterpreted to extend the
se of CAS in these patients. More specifically, the ESC
uideline provides a weak recommendation for CAS as an
lternative to CEA in high-volume centers with docu-
ented death or stroke rate 3%.3 Similarly, although the
CC/AHA guideline mentions that the effectiveness of
AS compared with BMT is not yet well-established, it still
ecommends that prophylactic CASmight be considered in
highly selected” asymptomatic patients (ie, patients at
igh surgical risk).1 A list of these selected patients is
rovided. It is worth mentioning that among the patients
onsidered “high-risk” are individuals with 50% con-
ralateral carotid stenosis.1
Before the SVS endorsed the ACC/AHA Guidelines,1
he SVS Executive Committee raised the issue of rewriting
he word “alternative.”21 This was, however, considered
ounterproductive because the document would have to be
eturned to all 16 sponsoring societies for altering a single
ord.21 Subsequently, the SVS published its updated
uideline for the management of carotid artery disease,
R1
1
1
1
1
1
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carotid stenosis who are candidates for intervention, CEA is
preferred to CAS for reduction of all-cause stroke and
periprocedural death (grade I; level of evidence, B).”2
Furthermore, the SVS clearly stated that CEA is the treat-
ment of choice for patients with symptomatic carotid ste-
nosis who are at acceptable risk for surgery.21
The diversity in the recommendations of the five 2011
guidelines1-5 suggests that the optimal management of
symptomatic and asymptomatic carotid stenosis is still a
controversial subject. A likely reason for the differences
seen in the five 2011 guidelines may be possible bias in
the interpretation of the existing trial results. Further-
more, there seems to be a difference in perception or precise
content between some “multispecialty”1 vs “single-
specialty”2,4 documents; single-specialty documents2,4
seem to be more definitive than “multispecialty” ones (eg,
the ACC/AHA Guidelines1).
Obviously, additional trials are needed to resolve these
controversies. These future trials will have to be designed
with care to provide information that will clearly define the
role for CAS in symptomatic and asymptomatic patients.
For example, CAS will likely get better results with its
restriction to younger patients (age 70 years),12 use of
better stents (membrane or mesh-covered), and with wider
use of better embolic protection devices. Furthermore,
with asymptomatic disease, we need to identify patients at
high risk of stroke so that they can be treated without
subjecting most carotid stenosis patients to CAS or CEA.
Future trials in asymptomatic patients comparing CAS,
CEA, and BMT should possibly be restricted to such high-
risk patients.
CONCLUSIONS
The uncertainty in the role of BMT in asymptomatic
patients, the disagreement in the five most recent guide-
lines, and the likelihood of ongoing and future improve-
ments in CAS make it possible that the 2011 carotid
guidelines may turn out to be misleading or incorrect. As
shown by current evidence, the updated SVS2 and the
Australasian4 guidelines address the issue of the proper
management of symptomatic and asymptomatic carotid
patients in the most optimal way. Nevertheless, these
guidelines may also need to be revised in the future as
improvements in CAS occur and the results of randomized
controlled trials emerge regarding the efficacy of CAS vs
CEA vs BMT alone in asymptomatic patients.
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2011;54:543-5.ubmitted Nov 21, 2011; accepted Jan 14, 2012.INVITED COMMENTARYRichard P. Cambria, MD, Boston, Mass
The debate about the appropriate management of carotid
bifurcation disease not only continues but has intensified related to
a number of events over the past 18 months. These include (1)
publication of the Carotid Revascularization Endarterectomy Ver-
sus Stenting Trial (CREST) trial results, including the important
follow-up studies emphasizing the clear-cut differences in symp-
tomatic vs asymptomatic patients with regard to periprocedural
complications of stroke and death; (2) publication of multiple
guideline documents during the calendar year 2011, as reviewed
by the authors; (3) increasing emphasis in some quarters to the
claim that best/modern medical therapy is sufficient treatment (ie,
without any intervention) in asymptomatic patients; and, (4) fur-
ther considerations by the Centers for Medicare & Medicaid
Services (CMS) in the form of a CMS Medical Evidence Develop-
ment and Coverage Analysis Committee (MEDCAC) meeting
that was held January 25, 2012. The MEDCAC panel heard
testimony on multiple viewpoints from a variety of stakeholders
involved in the management of carotid disease. The Society of
Vascular Surgery (SVS) was very involved at a high level in the
CMS MEDCAC and provided its views regarding this issue.
The authors appropriately emphasize that single-specialty
practice guidelines tend to be more definitive and declarative than
those produced by consensus in multispecialty-type documents.
The authors emphasize1 the prior discussions SVS held with the
American College of Cardiology/American Heart Association
Guidelines principal authors (Drs Brott and Halperin) and the
basis of those conversations resulting in SVS endorsement of this
very comprehensive document. Just as has been true in the multi-
ple discussions about the CREST trial results, comparison of the
guideline documents reviewed by the authors is very much an “eye
of the beholder” phenomenon.
In their article, the authors cite such obfuscation when they
review, for example, a recommendation from one of the docu-
ments, which characterizes the use of carotid artery stenting (CAS)
in asymptomatic patients as “might be reasonable in highly se-
lected patients . . . , but its effectiveness compared to best medical
therapy is not well studied.” Such a recommendation is obviouslynd the subject of a highly polarizing debate among those who
old different viewpoints.
It is important to emphasize, as the authors have done, that
uidelines published in 2011 can only reflect the best available and
igh-level evidence (ie, that gleaned from well-performed, ran-
omized, clinical trials). Accordingly, the SVS guidelines support
arotid endarterectomy in properly selected asymptomatic patients
largely based on the impressive data in the Asymptomatic Carotid
urgery Trial (ACST). Alternatively, the vocal claim that optimal
odern medical therapy produces equivalent or better results is
ased on a compendium of studies from an evidence base that can
e collectively criticized as containing many patients with degrees
f asymptomatic stenosis for whom intervention would never be
ecommended by current SVS practice guidelines.
Although I agree with the authors that the guidelines they
ave reviewed can be considered to have very different recommen-
ations, they can also be considered to have very similar recom-
endations, depending on how one chooses to interpret words
ike “alternative.” At the other end of the spectrum, in asymptom-
tic patients, the United Kingdom National Institute of Health
nd Clinical Excellence guidelines, for example, unequivocally
tate that CAS for asymptomatic patients should only be per-
ormed in the context of well-designed and approved clinical trials.
No doubt, we are once again in the midst of great controversy
n the management of, in particular, asymptomatic carotid stenosis
nd the overall role of CAS. It is worth emphasizing that SVS has
dentified the management of asymptomatic carotid stenosis as its
ingle most important clinical research priority. It is also clear that
anagement of carotid disease has been a core element of vascular
urgery practice ever since the original description of the patho-
natomic relationship between carotid atherosclerosis and stroke in
951. Sixty years later, the debate continues, and vascular surgeons
ust remain involved in the study of all of these controversies
oving forward.
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